Skip to main content
Cohance Lifesciences Limited (NSE:COHANCE)
India flag India · Delayed Price · Currency is INR
467.55
-25.75 (-5.22%)
Apr 29, 2026, 3:29 PM IST

Cohance Lifesciences Revenue

Cohance Lifesciences had revenue of 5.45B INR in the quarter ending December 31, 2025, with 77.29% growth. This brings the company's revenue in the last twelve months to 10.79B, up 2.90% year-over-year. In the fiscal year ending March 31, 2025, Cohance Lifesciences had annual revenue of 11.98B with 13.91% growth.

Revenue (ttm)
10.79B
Revenue Growth
+2.90%
P/S Ratio
16.58
Revenue / Employee
8.90M
Employees
1,212
Market Cap
178.87B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 31, 202511.98B1.46B13.91%
Mar 31, 202410.51B-2.89B-21.56%
Mar 31, 202313.40B201.07M1.52%
Mar 31, 202213.20B3.11B30.75%
Mar 31, 202110.10B1.76B21.10%
Mar 31, 2020 Pro Pro Pro
Mar 31, 2019 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Alembic Pharmaceuticals 72.67B
Eris Lifesciences 30.65B
NATCO Pharma 45.63B
Alivus Life Sciences 25.12B
Piramal Pharma 88.71B
Wockhardt 31.74B
Strides Pharma Science 47.26B
Gland Pharma 61.13B
Revenue Rankings

Cohance Lifesciences News

More News